An LMU research team led by Professor Olivia M. Merkel, Chair of Drug Delivery at LMU, has developed a new delivery system ...

The Farapoint device adds another tool to the company’s pulsed field ablation portfolio that could help increase or sustain ...

The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...

Tourmaline went public in 2023 via a reverse merger with the struggling cell therapy developer Talaris. The deal gave Tourmaline funds to develop pacibekitug, an antibody that targets interleukin-6, a ...

As part of the first-in-human trial, participants received more than 15 times the standard dose of the chemotherapy drug doxorubicin every 21 days for up to one year. “Usually, a patient can only ...

Knowledge graphs are a powerful tool for bringing together information from biological databases and linking what is already known about genes, diseases, treatments, molecular pathways and symptoms in ...

A man living at San Patrignano tends to the grounds. (Wilson Santinelli for WBUR) WBUR's Deborah Becker visits a community in the north of Italy, thought to be a model for these kinds of addiction ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated’s (NASDAQ: CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The hypertrophic cardiomyopathy ...

Cytokinetics Inc. won US approval for a drug to treat a deadly heart condition, posing a potential threat to sales of a similar Bristol Myers Squibb Co. treatment that’s expected to be a key growth ...